Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 1, 2005, Pages 96-103

  Gebo, Kelly A ^a   Fleishman, John A ^b   Conviser, Richard ^c   Reilly, Erin D ^a   Korthuis, P Todd ^d   Moore, Richard D ^a   Hellinger, James ^e   Keiser, Philip ^f   Rubin, Haya R ^a   Crane, Lawrence ^g   Hellinger, Fred J ^b   Mathews, W Christopher ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Community Medical Alliance ^*  (United States)

^f PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

African American; Disparities; Female; Gender; Highly active antiretroviral therapy; Injection drug use; Race

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; DRUG UTILIZATION; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; OUTPATIENT CARE; PHARMACY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK; SEX DIFFERENCE; T LYMPHOCYTE;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SAMPLING STUDIES; SEX CHARACTERISTICS; UNITED STATES;

EID: 19944428999     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200501010-00017     Document Type: Article

References (45)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
4. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
5. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531-1532.
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Supplemental Report, vol. 7. Atlanta: Centers for Disease Control and Prevention; 2001.
7. Hargraves JL, Cunningham PJ, Hughes RG. Racial and ethnic differences in access to medical care in managed care plans. Health Serv Res. 2001;36:853-868.
8. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001;135:352-366.
9. Schneider EC, Cleary PD, Zaslavsky AM, et al. Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites? JAMA. 2001;286:1455-1460.
10. Garg PP, Diener-West M, Powe NR. Reducing racial disparities in transplant activation: whom should we target? Am J Kidney Dis. 2001;37:921-931.
11. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med. 1991;6:35-40.
12. McLaughlin TJ, Soumerai SB, Weinrib D, et al. The association between primary source of ambulatory care and access to outcomes of treatment among AIDS patients. Int J Qual Health Care. 1999;11:293.
13. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res. 1995;30:593-614.
14. Graham NM, Jacobson LP, Kuo V et al. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol. 1994;47:1003-1012.
15. Moore RD, Stanton D, Gopalan R, et al. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763-768.
16. Jeffe DB, Meredith KL, Mundy LM, et al. Factors associated with HIV-infected patients' recognition and use of HIV medications. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:350-360.
17. Sambamoorthi U, Moynihan PJ, McSpiritt E, et al. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health. 2001;91:1474.
18. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
19. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000;25:115-123.
20. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
21. Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv Res. 1999;34:123-144.
22. Turner BJ, Newschaffer CJ, Zhang D, et al. Translating clinical trial results into practice: the effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women. Ann Intern Med. 1999;130:979-986.
23. Anderson KH, Mitchell JM. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med. 2000;160:3114.
24. Weissman JS, Makadon HJ, Seage GR III, et al. Changes in insurance status and access to care for persons with AIDS in the Boston Health Study. Am J Public Health. 1994;84:1997.
25. Katz MH, Chang SW, Buchbinder SP, et al. Health insurance and use of medical services by men infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:58-63.
26. Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res. 1993;28:543-561.
27. Solomon L, Stein M, Flynn C, et al. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:253-261.
28. Sambamoorthi U, Warner LA, Crystal S, et al. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug Alcohol Depend. 2000;60:77-89.
29. Kass N, Flynn C, Jacobson L, et al. Effect of race on insurance coverage and health service use for HIV-infected gay men. J Acquir Immune Defic Syndr. 1999;20:85-92.
30. Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911-925.
31. Sorvillo F, Kerndt P, Odem S, et al. Use of protease inhibitors among persons with AIDS in Los Angeles County. AIDS Care. 1999;11:147-155.
32. Smith MY, Rapkin BD, Winkel G, et al. Housing status and health care service utilization among low-income persons with HIV/AIDS. J Gen Intern Med. 2000;15:731-738.
33. Jacobson LP, Gore ME, Strathdee SA, et al. Therapy naivety in the era of potent antiretroviral therapy. J Clin Epidemiol. 2001;54:149-156.
34. Schwarz DF, Henry-Reid L, Houser J, et al. The association of perceived health, clinical status, and initiation of HAART (highly active antiretroviral therapy) in adolescents. J Adolesc Health. 2001;29(Suppl 3):115-122.
35. Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;117:233.
36. McNaghten AD, Hanson DL, Dworkin MS, et al. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:499-505.
37. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35:389-416.
38. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381.
39. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
40. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
41. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 1999;13:2547-2554.
42. Fairfield KM, Libman H, Davis RB, et al. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395-401.
43. Crystal S, Sambamoorthi U, Moynihan PJ, et al. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med. 2001;16:850-859.
44. Giordano TP, White AC, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr. 2003;32:399-405.
45. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.